Emcure Pharma Board Approves Amalgamation of Subsidiaries

Emcure Pharmaceuticals Limited's Board of Directors has approved a Composite Scheme of Amalgamation involving its wholly-owned subsidiaries, Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, with the parent company. The amalgamation aims to achieve entity rationalization and operational efficiency within the group. Zuventus Healthcare Limited had a net worth of ₹871.46 crore and a turnover of ₹1,040.58 crore for FY 2025-26. Emcutix Biopharmaceuticals Limited had a net worth of (₹13.07) crore and a turnover of ₹29.37 crore. Emcure Pharmaceuticals Limited reported a net worth of ₹3,710.60 crore and a turnover of ₹5,243.19 crore. No cash consideration will be paid as the entire share capital of the transferor companies is held by Emcure. The scheme is subject to necessary statutory and regulatory approvals, including from the National Company Law Tribunal (NCLT), Mumbai Bench. This amalgamation is considered exempt from related party transaction regulations.